Streetbeat News

Products Services

BIOR

Biora Therapeutics' award-winning abstract will be presented at the American College of Gastroenterology Annual Meeting, highlighting the company's innovative contributions to the field.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:18 pm

WKSP

Worksport Ltd. is progressing towards ISO 9000 certification, which could enhance its OEM relationships and sales opportunities with major car manufacturers like Rivian, Tesla, Ford, and others. The certification is expected by early-mid 2025.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:18 pm

WINT

Windtree Therapeutics announced positive Phase 2b clinical results for istaroxime, showing significant improvements in cardiac function and blood pressure in heart failure patients with early cardiogenic shock. The study met its primary endpoint, with istaroxime outperforming placebo in improving systolic blood pressure.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:17 pm

PERF

Perfect Corp. (NYSE:PERF) has partnered with Starboard Group to expand its AI-powered SkInsight skin analysis across 30 more ships, enhancing onboard beauty retail with personalized skincare solutions.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:16 pm

RMD

ResMed has launched the AirTouch N30i, its first fabric CPAP mask, designed to enhance comfort and encourage treatment adherence for sleep apnea patients. This innovation aims to improve sleep health for millions affected by sleep apnea.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:14 pm

MOS

Mosaic reported limited damage from Hurricane Helene at its Riverview facility, which is expected to resume full production in 10 days. The company is contributing $300K to Florida recovery efforts and offering employee assistance programs.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:14 pm

RLYB

Rallybio Corporation presented nonclinical data on ENPP1 inhibition as a therapeutic approach for hypophosphatasia at the ASBMR 2024 Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:13 pm

MBX

MBX Biosciences presented the rationale and design of its Phase 2 Avail trial for MBX 2109, a potential long-acting parathyroid hormone peptide prodrug for hypoparathyroidism, at the ASBMR 2024 Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:11 pm

PRME

Prime Medicine shares rose following a strategic collaboration with Bristol Myers Squibb to develop reagents for ex vivo T-cell therapies. The company is also focusing its pipeline on high-value programs.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:10 pm

ATXS

Astria Therapeutics has received FDA Orphan Drug Designation for its drug navenibart, aimed at treating hereditary angioedema. The drug has shown promising results in reducing attack rates in clinical trials.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:10 pm